Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 252 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eye Movement Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Study of Eye Movement Testing and Therapy

NCT00472485
View directory record Official record
Conditions
Saccadic Eye Movement Deficiency, Oculomotor Deficiency, Oculomotor Dysfunction
Interventions
eye movement therapy
Procedure
Lead sponsor
Ohio State University
Other
Eligibility
8 Years to 13 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 3, 2008 · Synced Oct 25, 2026, 2:42 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

NCT02189720
View directory record Official record
Conditions
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
Interventions
Amifampridine Phosphate
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational

Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings

NCT06093490
View directory record Official record
Conditions
Absence Epilepsy, Childhood, Absence Seizures, Absence Epilepsy, Epilepsy in Children, Staring, Seizures
Interventions
Eysz Hyperventilation Recorder
Device
Lead sponsor
Eysz, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
65 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational

4 Repeat Tauopathy Neuroimaging Initiative

NCT01804452
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Observational Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 25, 2026, 2:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

NCT07863180
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy(PSP)
Interventions
Tributyrin, Placebo
Drug
Lead sponsor
Prabesh Kanel
Other
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Convergence Insufficiency Treatment Study (CITS)

NCT01515943
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Active home-based computer vergence/accommodative therapy, Near target push-ups, Placebo home-based computer vergence/accommodative therapy, Placebo yoked prism flippers
Other · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
9 Years to 17 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Cranberry TWP, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 25, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

NCT06760546
View directory record Official record
Conditions
Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner

NCT01832883
View directory record Official record
Conditions
Amblyopia, Strabismus
Interventions
Pediatric Vision Scanner
Device
Lead sponsor
Rebiscan, Inc.
Industry
Eligibility
3 Years to 8 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational

Cognitive Impairement In Frontotemporal Dementia

NCT03452956
View directory record Official record
Conditions
Frontotemporal Degeneration, Progressive Supranuclear Palsy, Multiple System Atrophy
Interventions
None-Observation Only
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
997 participants
Timeline
2003 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 25, 2026, 2:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Objective Assessment of Disparity Vergence After Treatment of Symptomatic CI in Children

NCT03248336
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
office-based vergence/accommodative therapy
Procedure
Lead sponsor
Salus University
Other
Eligibility
9 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma

NCT02030522
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD)
Interventions
Accelerated Resolution Therapy (ART)
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
8
States / cities
Clearwater, Florida • Holiday, Florida • Jupiter, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 25, 2026, 2:42 AM EDT
Not yet recruiting No phase listed Observational

Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)

NCT07623837
View directory record Official record
Conditions
Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
Interventions
Glandy EOM (AI-based quantitative eye movement analysis software)
Device
Lead sponsor
THYROSCOPE INC.
Industry
Eligibility
22 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

NCT02460094
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 25, 2026, 2:42 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Interventions for Convergence Insufficiency in Concussed Children

NCT03908112
View directory record Official record
Conditions
Concussion, Convergence Insufficiency
Interventions
Standard Community Concussion Care (SC), SC plus Simple Convergence Exercises (SC+), SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)
Behavioral
Lead sponsor
Mitchell Scheiman
Other
Eligibility
11 Years to 17 Years
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
8
States / cities
Birmingham, Alabama • Fullerton, California • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Neural Disorders

NCT02761707
View directory record Official record
Conditions
Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions
Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational

Potential Research Participants for Future Studies of Inherited Eye Diseases

NCT00559234
View directory record Official record
Conditions
Cataract, Glaucoma, Retinitis Pigmentosa, Macular Degeneration, Strabismus
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational

Positive Exposure: A Photography and Video Intervention for Individuals With Craniofacial Differences

NCT00340964
View directory record Official record
Conditions
Craniofacial Differences
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
12 Years to 20 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational

Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.

NCT02132052
View directory record Official record
Conditions
Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive, Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 2Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

NCT01110720
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Davunetide, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
41 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 25, 2026, 2:42 AM EDT
Completed No phase listed Observational

International Guillain-Barré Syndrome Outcome Study

NCT01582763
View directory record Official record
Conditions
Guillain-Barré Syndrome, Miller Fisher Syndrome
Interventions
Not listed
Lead sponsor
Erasmus Medical Center
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 25, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Eye Muscle Surgery to Treat Congenital Nystagmus

NCT00001866
View directory record Official record
Conditions
Nystagmus
Interventions
horizontal muscles of the eye will be cut and then reattached in the same position
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Attention and Eye Movement in Parkinson's Disease

NCT06899022
View directory record Official record
Conditions
Essential Tremor, Parkinson's Disease (PD), Dystonias
Interventions
Normal therapeutic DBS, Reduced current DBS, Reduced frequency DBS
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 90 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

NCT03391765
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12, Placebo solution for IV infusion on Day 15
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 25, 2026, 2:42 AM EDT